Gufic BioSciences Shares Plunge 8.7% as Q3 Profit Disappoints Investors
Gufic BioSciences Ltd (GUFI.NS) shares tumbled 8.7% in early trade on February 17, 2025, following the release of its Q3 FY25 results. The pharmaceutical company reported a 13% year-on-year decline in net profit to ₹193.1 million, despite a 3.9% increase in revenue to ₹2.10 billion. The profit margin contracted to 9.2% from 11% in the same quarter last year. Analysts attribute the profit decline to rising expenses and increased competition in key segments. Despite the setback, Gufic maintains a strong order book and continues to focus on expanding its product portfolio in high-growth therapeutic areas.
Sources: Moneycontrol, Simply Wall St, Business Standard